The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on experimental therapies and challenging drug development programs, has fueled what some are calling "High Stakeholder Pharma." While the potential for revolutionary treatments and significant returns is clear, the linked risks are also significa… Read More